Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / An Evidence-Based Review of Galcanezumab for the Treatment of Migraine.

< BACK TO ARCHIVE


Papers: 3 Oct 2020 - 9 Oct 2020


Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Oct 03


Neurol Ther


http://www.ncbi.nlm.nih.gov/pubmed/33010021?dopt=Abstract

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine.

Authors

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine.
Urits I, Yilmaz M, Charipova K, Gress K, Bahrum E, Swett M, Berger AA, Kassem H, Ngo AL, Cornett EM, Kaye AD, Viswanath O
Neurol Ther. 2020 Oct 03.
PMID: 33010021.

Abstract

This is a comprehensive review of the current literature on the usage of galcanezumab for migraine treatment. It reviews the biology, pathophysiology, epidemiology, diagnosis, and conventional treatment of migraines, then compares the literature available for galcanezumab with historical treatment options.
Read This Paper